What is the treatment for Angiomyolipoma (AML) of the kidney?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2025 • View editorial policy

From the Guidelines

For patients with kidney angiomyolipoma, the most effective treatment approach is selective arterial embolization for tumors at risk of bleeding, while smaller asymptomatic tumors can be monitored with periodic imaging, and mTOR inhibitors like everolimus or sirolimus can be used for tuberous sclerosis complex-associated angiomyolipomas. The treatment of kidney angiomyolipoma depends on various factors including tumor size, symptoms, and patient-specific factors 1.

Key Considerations

  • Small asymptomatic angiomyolipomas (less than 4 cm) typically require only monitoring with periodic ultrasound or CT imaging every 6-12 months.
  • For larger tumors (greater than 4 cm), symptomatic cases, or those at risk of bleeding, active intervention is recommended, with selective arterial embolization being a preferred option due to its minimally invasive nature 1.
  • Nephron-sparing surgery (partial nephrectomy) to remove the tumor while preserving kidney function can also be considered, especially when the tumor is large or when arterial embolization is not feasible.
  • For patients with tuberous sclerosis complex-associated angiomyolipomas, mTOR inhibitors like everolimus (starting dose of 5 mg per day for adults and 2.5 mg/m2 for children) or sirolimus may be prescribed to reduce tumor size and prevent growth 2.

Treatment Approach

  • The choice of treatment should be tailored to both patient and tumor features, considering factors such as the risk of bleeding, tumor size, and patient comorbidities 3.
  • Pain management with standard analgesics may be needed for symptomatic cases.
  • Patients should be monitored for potential complications including spontaneous hemorrhage, which presents with flank pain, hematuria, and sometimes shock, requiring immediate medical attention.

Medication Dosage

  • Everolimus dosage can be adjusted based on side effects and safety, with a target trough level of 5–15 ng/ml 2.
  • Sirolimus can be used as an alternative to everolimus, with dosing aimed at achieving stable plasma levels of between 4 and 8 ng/ml 2.

From the FDA Drug Label

1.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma Everolimus tablets are indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery.

2.5 Recommended Dosage for Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma The recommended dosage of everolimus tablets is 10 mg orally once daily until disease progression or unacceptable toxicity.

The treatment for angiomyolipoma of the kidney is everolimus 10 mg orally once daily, in adult patients with Tuberous Sclerosis Complex (TSC), not requiring immediate surgery 4.

  • Key points:
    • Indication: Adult patients with renal angiomyolipoma and TSC
    • Dosage: 10 mg orally once daily
    • Duration: Until disease progression or unacceptable toxicity

From the Research

Treatment Options for Angiomyolipoma of the Kidney

  • The treatment of renal angiomyolipomas (AMLs) depends on the size of the lesion and the presence of symptoms 5, 6.
  • Current management options include observation, transcatheter embolization, and partial or total nephrectomy 5, 6.
  • Symptomatic or large (> 8 cm) masses typically require intervention, while small asymptomatic lesions (< 4 cm) can be monitored with serial imaging studies 6.

Embolization as a Treatment Option

  • Selective arterial embolization is considered a standard initial therapy for symptomatic renal AMLs 5.
  • Embolization can be used as a preventive treatment or in emergency settings, with significant reduction in tumor size during follow-up 7.
  • The procedure has a high technical success rate and is generally safe, with minor complications such as post-embolization syndrome (PES) being common 7.

Surgical Intervention

  • Surgical intervention, such as partial or total nephrectomy, may be necessary in cases of massive rebleeding or other complications 5, 8.
  • Minimally invasive surgical approaches, such as laparoscopic and percutaneous ablative therapies, are also available for nephron-sparing treatment of renal AMLs 9.

Factors Influencing Treatment Decisions

  • The presence of tuberous sclerosis complex (TSC) and intralesional aneurysms should be considered in treatment decisions, as they can affect the risk of complications and treatment outcomes 7, 6.
  • The size of the lesion is a significant factor in determining the need for treatment, with larger lesions being more likely to require intervention 6.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.